Panacos Begins Early Stage HIV Inhibitor Study
Posted on: Tuesday, 27 February 2007, 15:01 CST
Panacos Pharmaceuticals has initiated a phase I trial of its investigational maturation inhibitor for the treatment of HIV.
This phase I study is designed to evaluate the safety and pharmacokinetic properties of the inhibitor PA-040 in humans after a single dose. Maturation inhibition is a new target discovered by Panacos. The first-in-class HIV maturation inhibitor, bevirimat, has shown significant anti-HIV activity in HIV patients and is in phase IIb clinical testing.
The company's second-generation maturation inhibitor program is designed to develop chemical analogs of bevirimat with distinct pharmacological properties including the potential to have activity against HIV strains resistant to bevirimat, should these resistant strains appear in the clinic in the future.
"Having already demonstrated proof of concept of maturation inhibition with bevirimat, we plan to test several second generation compounds, including PA-040, in single dose testing and then select the optimum compound to take into multiple dose human studies," said Graham Allaway, Panacos' president and COO.
Source: Datamonitor
Related Articles
- Ambrilia to Present Its New HIV Integrase Inhibitors at the International HIV Drug Resistance Workshop
- Ambrilia Presents Latest Data on Its Novel HIV Integrase Inhibitors at the 47th ICAAC
- Gilead Announces 24-Week Results From Phase II Study of Investigational HIV Integrase Inhibitor GS 9137
- Panacos Begins Phase 1 Clinical Study of Second Generation Maturation Inhibitor PA-040
- Gilead Announces Completion of Phase II Clinical Trial of Novel Investigational HIV Integrase Inhibitor GS 9137
- Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients With Limited Available Treatment Options; Worldwide Access Program Will Be Conducted Along With Phase III Studies
- Panacos Presents Progress on HIV Fusion Inhibitor Program at International AIDS Conference
- Gilead Announces the Advancement of HIV Integrase Inhibitor GS 9137 to a Phase II Clinical Trial
- Samaritan's Oral HIV Entry Inhibitor Noted As a Show ''Out of the Gate'' in the Race for Approval
- Progenics Completes Enrollment in Phase 1 Clinical Trial of PRO 140, a Novel HIV Entry Inhibitor Targeting CCR5 - Potent Synergy Reported Between PRO 140 and Small-Molecule CCR5 Antagonists -
 |
 |
User Comments (0)
RSS Feeds